{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:24:06Z","timestamp":1791098646762,"version":"4.1.0"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,9]]},"abstract":"ABSTRACT<\/jats:title>\n \n Ceftaroline is a new cephalosporin with broad-spectrum activity against Gram-positive and -negative organisms. The prodrug of ceftaroline, ceftaroline fosamil, combined with the \u03b2-lactamase inhibitor avibactam (formerly NXL104), was tested against\n Enterobacteriaceae<\/jats:named-content>\n strains producing Ambler class A, B, C, and D enzymes, including strains producing multiple enzymes, as well as\n Pseudomonas aeruginosa<\/jats:named-content>\n ,\n Acinetobacter<\/jats:named-content>\n spp., and methicillin-susceptible and methicillin-resistant\n Staphylococcus aureus<\/jats:named-content>\n (MRSA) strains. Isolates were collected from 1999 to 2008 from global surveillance programs, and susceptibility testing was performed by reference broth microdilution methods. Ceftaroline-avibactam exhibited potent activity against\n Enterobacteriaceae<\/jats:named-content>\n producing various \u03b2-lactamase types (MIC\n 90<\/jats:sub>\n , 0.25 to 2 \u03bcg\/ml, except for metalloenzymes), including 99 strains carrying multiple enzymes (2 to 4 \u03b2-lactamases; MIC\n 90<\/jats:sub>\n , 2 \u03bcg\/ml). All isolates were inhibited by ceftaroline-avibactam at \u22644 \u03bcg\/ml. Ceftaroline-avibactam (MIC\n 90<\/jats:sub>\n , 0.5 to 1 \u03bcg\/ml) was more active than meropenem (MIC\n 90<\/jats:sub>\n , >8 \u03bcg\/ml) and other comparators when tested against KPC-producing strains.\n S. aureus<\/jats:named-content>\n strains, including MRSA with four staphylococcal cassette chromosome\n mec<\/jats:italic>\n (SCC\n mec<\/jats:italic>\n ) types, were dominantly (99.1%) inhibited by ceftaroline-avibactam at \u22642 \u03bcg\/ml, and the ceftaroline MIC was not adversely affected by the addition of the \u03b2-lactamase inhibitor (MIC\n 50\/90<\/jats:sub>\n , 1 and 2 \u03bcg\/ml for ceftaroline with and without avibactam). Ceftaroline-avibactam demonstrated limited activity against\n Acinetobacter<\/jats:named-content>\n spp. and\n P. aeruginosa<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n s, 32 and 16 \u03bcg\/ml, respectively). These results document that ceftaroline-avibactam has potent activity against\n Enterobacteriaceae<\/jats:named-content>\n that produce KPC, various ESBL types (CTX-M types), and AmpC (chromosomally derepressed or plasmid-mediated enzymes), as well as against those producing more than one of these \u03b2-lactamase types, and its development as a therapeutic option for the treatment of infections caused by multidrug-resistant\n Enterobacteriaceae<\/jats:named-content>\n as well as MRSA is warranted.\n <\/jats:p>","DOI":"10.1128\/aac.00817-12","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T07:48:33Z","timestamp":1340783313000},"page":"4779-4785","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":70,"title":["Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More \u03b2-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome\n mec<\/i>\n Types"],"prefix":"10.1128","volume":"56","author":[{"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq251"},{"key":"e_1_3_2_3_2","volume-title":"Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.","author":"Castanheira M","year":"2011","unstructured":"CastanheiraM FarrellSE MendesRE JonesRN. 2011. Contemporary (2010) diversity of \u03b2-lactamases among Enterobacteriaceae collected from bacteremias in U.S.A. hospitals: report from the SENTRY program, abstr. C2-1250. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 12\u201315, September 2011."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2008.0827"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr081"},{"key":"e_1_3_2_6_2","unstructured":"Clinical and Laboratory Standards Institute. 2009. M07\u2013A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: 8th ed. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_7_2","unstructured":"Clinical and Laboratory Standards Institute. 2012. M100\u2013S22. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq254"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr098"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-09"},{"key":"e_1_3_2_11_2","unstructured":"EUCAST. 2011. European Committee on Antimicrobial Susceptibility Testing. 2012. Breakpoint tables for interpretation of MICs and zone diameters version 2.0. EUCAST Basel Switzerland. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 1 January 2012."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn320"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01384-09"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00275-07"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq161"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.6.2153-2162.2002"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2009.08.001"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq255"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.004"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00817-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00817-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:07:32Z","timestamp":1645481252000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00817-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1128\/AAC.00817-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00817-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"2012-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}